MAPKs ERK and p38, but not JNK Phosphorylation, Modulate IL-6 and TNF-α Secretion Following OK-432 In Vitro Stimulation of Purified Human Monocytes

Scandinavian Journal of Immunology

Volumn 74, Issue 2, 2011, Pages 114-125

  Olsnes, C ^a   Olofsson, J ^a,b   Aarstad, H J ^a,b,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PICIBANIL; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MONOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTHRACENES; ANTINEOPLASTIC AGENTS; BUTADIENES; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; PHOSPHORYLATION; PICIBANIL; PYRIDINES; TEICHOIC ACIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960090346     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02555.x     Document Type: Article

References (45)

1. Gonzalez-Mejia ME, Doseff AI. Regulation of monocytes and macrophages cell fate. Front Biosci 2009;14:2413-31.
2. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G et al. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 2006;211:487-501.
3. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002;188:9-21.
4. Okamoto M, Ohe G, Oshikawa T et al. Induction of Th1-type cytokines by lipoteichoic acid-related preparation isolated from OK-432, a penicillin-killed streptococcal agent. Immunopharmacology 2000;49:363-76.
5. Baran J, Baj-Krzyworzeka M, Weglarczyk K, Ruggiero I, Zembala M. Modulation of monocyte-tumour cell interactions by Mycobacterium vaccae. Cancer Immunol Immunother 2004;53:1127-34.
6. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem 2000;7:715-29.
7. Moschos SJ, Edington HD, Land SR et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006;24:3164-71.
8. Knecht R, Peters S, Solbach C, Baghi M, Gstottner W, Hambek M. EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Anticancer Res 2003;23:4789-95.
9. Sakamoto J, Teramukai S, Watanabe Y et al. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer. J Immunother 2001;24:250-6.
10. Kim MG, Kim SG, Lee JH, Eun YG, Yeo SG. The therapeutic effect of OK-432 (picibanil) sclerotherapy for benign neck cysts. Laryngoscope 2008;118:2177-81.
11. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 2007;56:905-11.
12. Kumazawa H, Yamashita T, Tachikawa T, Minamino M, Nakata Y. Local injection of OK-432/fibrinogen gel into head and neck carcinomas. Eur J Cancer 1994;30A:1741-4.
13. Naito K, Ueda Y, Itoh T et al. Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity. Int J Oncol 2006;28:1481-9.
14. Laranne J, Keski-Nisula L, Rautio R, Rautiainen M, Airaksinen M. OK-432 (Picibanil) therapy for lymphangiomas in children. Eur Arch Otorhinolaryngol 2002;259:274-8.
15. Ogita S, Tsuto T, Deguchi E, Tokiwa K, Nagashima M, Iwai N. OK-432 therapy for unresectable lymphangiomas in children. J Pediatr Surg 1991;26:263-8; discussion 8-70.
16. Knipping S, Goetze G, Neumann K, Bloching M. Sclerotherapy of cervical cysts with Picibanil (OK-432). Eur Arch Otorhinolaryngol 2007;264:423-7.
17. Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res 2004;24:3295-301.
18. Cleary PP. Streptococcus moves inward. Nat Med 2006;12:384-6.
19. Olsnes C, Stavang H, Olofsson J, Aarstad HJ. TNF-alpha is secreted by monocytes in transit to become macrophages, but not by peripheral blood monocytes, following OK-432 (lyophilized S. pyogenes) stimulation. Scand J Immunol 2007;66:684-93.
20. Olsnes C, Stavang H, Brokstad K, Olofsson J, Aarstad HJ. Chemokines are secreted by monocytes following OK-432 (lyophilized Streptococcus pyogenes) stimulation. BMC Immunol 2009;10:6.
21. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16:3-9.
22. Yang CS, Lee JS, Song CH et al. Protein kinase C zeta plays an essential role for Mycobacterium tuberculosis-induced extracellular signal-regulated kinase 1/2 activation in monocytes/macrophages via Toll-like receptor 2. Cell Microbiol 2007;9:382-96.
23. Irish JM, Anensen N, Hovland R et al. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 2007;109:2589-96.
24. Krutzik PO, Crane JM, Clutter MR, Nolan GP. High-content single-cell drug screening with phosphospecific flow cytometry. Nat Chem Biol 2008;4:132-42.
25. Irish JM, Hovland R, Krutzik PO et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004;118:217-28.
26. Li H, Nooh MM, Kotb M, Re F. Commercial peptidoglycan preparations are contaminated with superantigen-like activity that stimulates IL-17 production. J Leukoc Biol 2008;83:409-18.
27. Hironaka K, Yamaguchi Y, Okita R, Okawaki M, Nagamine I. Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432. Anticancer Res 2006;26:3701-7.
28. Banerjee A, Gugasyan R, McMahon M, Gerondakis S. Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc Natl Acad Sci U S A 2006;103:3274-9.
29. Grasset MF, Gobert-Gosse S, Mouchiroud G, Bourette RP. Macrophage differentiation of myeloid progenitor cells in response to M-CSF is regulated by the dual-specificity phosphatase DUSP5. J Leukoc Biol 2010;87:127-35.
30. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006;211:609-18.
31. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol 2002;20:825-52.
32. Aomatsu K, Kato T, Fujita H et al. Toll-like receptor agonists stimulate human neutrophil migration via activation of mitogen-activated protein kinases. Immunology 2008;123:171-80.
33. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood 2008;112:935-45.
34. Song X, Tanaka S, Cox D, Lee SC. Fcgamma receptor signaling in primary human microglia: differential roles of PI-3K and Ras/ERK MAPK pathways in phagocytosis and chemokine induction. J Leukoc Biol 2004;75:1147-55.
35. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310.
36. Meja KK, Seldon PM, Nasuhara Y et al. p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism. Br J Pharmacol 2000;131:1143-53.
37. Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005;5:921-8.
38. Adhikary G, Sun Y, Pearlman E. C-Jun NH2 terminal kinase (JNK) is an essential mediator of Toll-like receptor 2-induced corneal inflammation. J Leukoc Biol 2008;83:991-7.
39. Zhang H, Shi X, Hampong M, Blanis L, Pelech S. Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase. J Biol Chem 2001;276:6905-8.
40. Miranda MB, Xu H, Torchia JA, Johnson DE. Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway. Leuk Res 2005;29:1293-306.
41. Cao J, Chen T, Gong Y et al. Molecular mechanisms of the secretion of cytokines and chemokines from human monocytes activated by pneumococcal surface protein A (PspA): roles of mitogen-activated protein kinases and NF-kappaB. Microb Pathog 2010;48:220-9.
42. Pan K, Wang H, Liu WL et al. The pivotal role of p38 and NF-kappaB signal pathways in the maturation of human monocyte-derived dendritic cells stimulated by streptococcal agent OK-432. Immunobiology 2009;214:350-8.
43. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14:342-6.
44. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40.
45. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009;4:28-35.